Abstract
There is an obvious need to develop efficient countermeasure agents for use in emergency situations or as adjuncts to radiotherapy to protect healthy tissues from the consequences of an irradiation. To this end, we have investigated the capacity of norbadione A, a polyphenol extracted from the edible mushroom Bay boletus to reduce the toxicity of ionizing radiation towards cultured cells and whole-body exposed mice. Results indicate that this compound could slightly enhance the resistance of TK6 lymphoid cells to radiation and increase the survival rate in lethally irradiated mice. However, norbadione A was found to be cytotoxic at concentrations over 30 μM in vitro. The acute toxicity of this compound also precluded its use at higher doses for enhanced in vivo radioprotection. Norbadione A may nevertheless serve as lead for development of less toxic analogs with potentially cytoprotective/radioprotective activities.
Keywords: Norbadione A, Polyphenol, Radioprotective agent, Lymphocytes, radioprotective, polyphenol norbadione A, TK6, Fukushima's nuclear plant, conventional radiotherapy, sulfhydryl compounds, experimental radioprotective arsenal, reactive oxygen species (ROS), Resveratrol, Xerocomus badius
Letters in Drug Design & Discovery
Title: Evaluation of the Radioprotective Potential of the Polyphenol Norbadione A
Volume: 9 Issue: 1
Author(s): Antoine Le Roux, Elodie Josset, Sami Benzina, Brice Nadal, Marine Desage-El Murr, Benoit Heurtaux, Frederic Taran, Jean-Marc Denis, Thierry Le Gall, Stephane Meunier and Pierre Bischoff
Affiliation:
Keywords: Norbadione A, Polyphenol, Radioprotective agent, Lymphocytes, radioprotective, polyphenol norbadione A, TK6, Fukushima's nuclear plant, conventional radiotherapy, sulfhydryl compounds, experimental radioprotective arsenal, reactive oxygen species (ROS), Resveratrol, Xerocomus badius
Abstract: There is an obvious need to develop efficient countermeasure agents for use in emergency situations or as adjuncts to radiotherapy to protect healthy tissues from the consequences of an irradiation. To this end, we have investigated the capacity of norbadione A, a polyphenol extracted from the edible mushroom Bay boletus to reduce the toxicity of ionizing radiation towards cultured cells and whole-body exposed mice. Results indicate that this compound could slightly enhance the resistance of TK6 lymphoid cells to radiation and increase the survival rate in lethally irradiated mice. However, norbadione A was found to be cytotoxic at concentrations over 30 μM in vitro. The acute toxicity of this compound also precluded its use at higher doses for enhanced in vivo radioprotection. Norbadione A may nevertheless serve as lead for development of less toxic analogs with potentially cytoprotective/radioprotective activities.
Export Options
About this article
Cite this article as:
Le Roux Antoine, Josset Elodie, Benzina Sami, Nadal Brice, Desage-El Murr Marine, Heurtaux Benoit, Taran Frederic, Denis Jean-Marc, Le Gall Thierry, Meunier Stephane and Bischoff Pierre, Evaluation of the Radioprotective Potential of the Polyphenol Norbadione A, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798192900
DOI https://dx.doi.org/10.2174/157018012798192900 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pharmacological Treatment of Cachexia
Current Drug Targets Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Telomerase and Survivin in Colorectal and Pancreatic Cancer – Biomarkers of Life and Death in the Balance Between Proliferation and Apoptosis
Current Cancer Therapy Reviews Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Motor Neuron Disease and Acquired Axonal Neuropathy Association in HIV Infection: Case Report and Update
Current HIV Research Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Intracellular Trafficking of Plasmids for Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import
Current Gene Therapy Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
Current Topics in Medicinal Chemistry Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders
Current Drug Targets - Cardiovascular & Hematological Disorders Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Current Cancer Therapy Reviews